Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Capital Expenditures (2024 - 2025)

Maze Therapeutics has reported Capital Expenditures over the past 2 years, most recently at $760000.0 for Q4 2025.

  • Quarterly Capital Expenditures fell 19.06% to $760000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $794000.0 through Dec 2025, down 30.78% year-over-year, with the annual reading at $794000.0 for FY2025, 30.78% down from the prior year.
  • Capital Expenditures was $760000.0 for Q4 2025 at Maze Therapeutics, up from -$658000.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $939000.0 in Q4 2024 and troughed at -$658000.0 in Q3 2025.